Quick Answer
IRONWOOD PHARMACEUTICALS INC reported Cash and Equivalents of $215.46 million for fiscal year 2025.
IRONWOOD PHARMACEUTICALS INC Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $215.46M | +143.3% |
| 2024 | $88.56M | -3.9% |
| 2023 | $92.15M | -86.0% |
| 2022 | $656.20M | +5.8% |
| 2021 | $620.13M | +71.0% |
| 2020 | $362.56M | +104.8% |
| 2019 | $177.02M | +2.2% |
| 2018 | $173.17M | +37.7% |
| 2017 | $125.74M | +132.8% |
| 2016 | $54.00M | -79.3% |
| 2015 | $261.29M | +251.7% |
| 2014 | $74.30M | -1.6% |
| 2013 | $75.49M | -44.8% |
| 2012 | $136.70M | +56.6% |
| 2011 | $87.28M | +96.9% |
| 2010 | $44.32M | -63.8% |
| 2009 | $122.31M | +84.4% |
| 2008 | $66.33M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $140.41M | +59.2% | +51.2% |
| June 30, 2025 | $92.85M | -12.0% | -14.4% |
| March 31, 2025 | $108.48M | -10.7% | +22.5% |
| December 31, 2024 | $88.56M | -3.9% | +0.4% |
| September 30, 2024 | $88.21M | -19.9% | -16.4% |
| June 30, 2024 | $105.52M | -39.8% | -13.2% |
| March 31, 2024 | $121.54M | -83.6% | +31.9% |
| December 31, 2023 | $92.15M | -86.0% | -16.3% |
- IRONWOOD PHARMACEUTICALS INC showed an increase of +143.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, IRONWOOD PHARMACEUTICALS INC’s cash and equivalents has grown by 224.8% (from $66.33 million to $215.46 million).
- The most recent figure is from IRONWOOD PHARMACEUTICALS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: